. . . . "Magaldrato"@en . . "Aluminium oxide: absorbed Al ions are eliminated in the urine (0.1-0.5 mg of Al in aluminium-containing antacid is absorbed from standard daily doses of antacid) while insoluble or poorly absorbed Al salts in the intestines are excreted through the feces. Magnesium oxide: absorbed Mg ions (up to 30%) are eliminated in the urine, unabsorbed is excreted in the feces."@en . . . . . . . . . . . "1317-26-6"@en . . "Humans and other mammals"@en . . . . . "withdrawn"@en . . . . "# Kurtz W: [A layered lattice antacid with long-term effectiveness. Profile of action and safety exemplified by magaldrate]. Fortschr Med. 1993 Feb 28;111(6):93-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8462913 # Varas Lorenzo MJ, Lopez Martinez A, Gordillo Bernal J, Mundet Surroca J: [Comparative study of 3 drugs (aceglutamide aluminum, zinc acexamate, and magaldrate) in the long-term maintenance treatment (1 year) of peptic ulcer]. Rev Esp Enferm Dig. 1991 Aug;80(2):91-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1790087"@en . . . "Aluminum magnesium hydroxide hydrate"@en . . "Magaldrate"@en . . "Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market."@en . . . . . "U.S. Patent 2,923,660."@en . . . . "Magaldratum"@en .